Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a simple shot replace IV drips for nausea?

NCT ID NCT02466984

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether metoclopramide, a common anti-nausea drug, works as well when injected under the skin (subcutaneous) as when given through a vein (IV). Five patients in a palliative care unit received the drug both ways to compare absorption. The goal is to offer a more comfortable and convenient option for managing nausea and vomiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metoclopramide (Primperan)
What this could lead to
If it works, this could provide a simpler, less invasive way to give metoclopramide for nausea and vomiting in patients who cannot take oral medication.
What could go wrong
This is a very small study (5 participants) in a specific palliative care setting, so results may not apply broadly. The drug's effectiveness via subcutaneous route is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

5 people

The number who actually took part.

Started

Jul 2016

Finished

Feb 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Man or woman \> 18 years * Patients hospitalized at the palliative medical care unit of University Hospital Bordeaux * Patient whose life expectancy is greater to 4 weeks * Patients suffering from nausea the day of inclusion with a greater than or equal score to 3/10 on a numerical scale (FR) from 0 to 10 and / or have had at least one vomiting within three days prior to inclusion * Patients may be infused through an IV and subcutaneous (SC) * Patient can communicate verbally or in writing * Patients affiliates or beneficiaries of a social security fund * Patient has given his written consent Exclusion criteria * Pregnant or breastfeeding women * Current Treatment for severe and progressive threatening disease * Treatment with oral or injectable metoclopramide within 3 days prior to inclusion * Treatment with levodopa or dopamine agonists in progress * Neuroleptic Processing * Patient with lesion occlusive syndrome * Patients at risk of gastrointestinal perforation * Patient with clinical signs of gastrointestinal bleeding * Parkinson's disease * Patients with epilepsy not controlled by anti-seizure treatment * Patients suffering from liver failure * Patients with a heart rate less than 60 beats / min at baseline * Patients with systolic blood pressure less than or equal to 90 mmHg at baseline * History of allergy to metoclopramide * History of allergy to ondansetron * Previous history of tardive dyskinesia to neuroleptics or metoclopramide * Previous history of pheochromocytoma * Previous history of methemoglobinemia with metoclopramide * History of deficit NADH-cytochrome b5 reductase * Patient deprived of liberty by judicial or administrative decision * Major protected by law * Exclusion period Patient relative over another protocol. Exclusion criteria * Pregnant woman (blood β-HCG dosage ≥ 5 IU / L) * Patients with a creatinine clearance less than or equal to 60 mL / min at baseline * Patient with cardiac conduction disorders on ECG * Patients with electrolyte imbalance in electrolytes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nausea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Nausea Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Bordeaux - St André

    Bordeaux, Aquitaine, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.